statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at...

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Savara (SVRA, $4.84) price exceeded its 50-day Moving Average on April 01, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Savara (SVRA, $4.99) price moved above its 50-day Moving Average on March 28, 2024

Savara (SVRA, $4.8) price exceeded its 50-day Moving Average on March 22, 2024

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024...

Savara Announces New Employment Inducement Grant

Savara (SVRA, $4.89) price moved above its 50-day Moving Average on March 20, 2024

Savara (SVRA, $4.67) price exceeded its 50-day Moving Average on March 14, 2024

Savara Inc (NASDAQ:SVRA  Get Free Report)s stock price fell 5.5% during trading on Monday . The company traded as low as $4.97 and last traded at $5.01. 261,205 shares traded hands...

Savara (NASDAQ:SVRA)  Shares Down 5.5%

This is a signal that SVRA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Savara (SVRA, $4.92) Stochastic Oscillator left the oversold zone on March 12, 2024

This is a Bearish indicator signaling SVRA's price could decline from here. Traders may explore shorting the stock or put options...

Savara (SVRA, $4.91) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 11, 2024

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Volume	591,994.00
52-Wk High	$5.70
52-Wk Low	$1.83

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.10	--	--	N/A
Q4'23	-$0.10	-$0.09	12.90%	BEAT
Q3'23	-$0.07	-$0.10	-39.53%	MISSED
Q2'23	-$0.08	-$0.07	10.26%	BEAT
Q1'23	-$0.07	-$0.07	--	EXPECTED

SVRA Savara Inc

About

Feed

News

Sentiment

Earnings

Fundamentals